RDHL

RDHL

Last Updated:

Q3'20

RedHill Biopharma

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.

RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.

RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.

RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.

RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

Cash

$34.8M

Burn Rate (Qtr)

-$18.6

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Talicia® (omeprazole magnesium, amoxicillin and rifabutin)

Helicobacter pylori (H. pylori)

Quarterly Sales (Approved)

March 5, 2021 (Est)

Aemcolo® (rifamycin)

Diarrhea caused by non-invasive strains of Escherichia coli (E.coli)

Quarterly Sales (Approved)

March 5, 2021 (Est)

RHB-204

Nontuberculous Mycobacteria (NTM) Infections

Phase 3 Readout

TBD

RHB-104

Crohn's disease

NDA Submission

TBD

RHB-102 (Bekinda®)

Gastroenteritis & gastritis

Phase 3

TBD

RHB-107 (upamostat)

COVID-19

Phase 2/3 Initiation

Q4 2020

Opaganib (ABC294640, Yeliva®)

COVID-19

Phase 2/3 (Preliminary Data)

Q4 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

RDHL - RedHill Biopharma Provi...

Summary: Q3/2020 net revenues of approximately $21 million, with gross profit of $10.6 million, or approximately 51%, up from $6.7 million and approximately 32% in Q2/2020 Strong growth for Talicia® w...

RDHL - Positive Recommendation...

#RDHL announced that its U.S. Phase 2 study with #opaganib (#Yeliva®, #ABC294640)1 in patients hospitalized with severe #COVID-19 pneumonia, has successfully passed the first scheduled independent Saf...

RDHL - Opaganib COVID-19 Study...

#RDHL announced that the "U.S. Phase 2 study with opaganib (Yeliva®, ABC294640)1 in patients hospitalized with severe COVID-19 pneumonia has passed its second pre-scheduled safety review by the indepe...

RDHL - Brazil Approves RedHill...

#RDHL announced "approval from the Brazilian Health Regulatory Agency (ANVISA) for its ongoing global Phase 2/3 study evaluating opaganib1 in patients hospitalized with severe COVID-19 pneumonia. Opag...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon